Aster Capital Management DIFC Ltd Takes $1.85 Million Position in Biogen Inc. $BIIB

Aster Capital Management DIFC Ltd acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, Holdings Channel reports. The firm acquired 10,487 shares of the biotechnology company’s stock, valued at approximately $1,846,000. Biogen comprises approximately 0.8% of Aster Capital Management DIFC Ltd’s investment portfolio, making the stock its 18th biggest holding.

Several other hedge funds also recently modified their holdings of the stock. Rothschild Investment LLC increased its stake in shares of Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 56 shares in the last quarter. Itau Unibanco Holding S.A. grew its position in Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 66 shares during the period. Advisory Services Network LLC grew its position in Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares during the period. Davis Investment Partners LLC grew its position in Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares during the period. Finally, Optas LLC grew its position in Biogen by 4.5% in the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 73 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

BIIB opened at $198.64 on Tuesday. The firm’s fifty day moving average price is $189.16 and its two-hundred day moving average price is $184.48. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a market capitalization of $29.33 billion, a price-to-earnings ratio of 21.31 and a beta of 0.20. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on BIIB. Guggenheim lifted their price target on shares of Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. lifted their price target on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. The Goldman Sachs Group lifted their price target on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Oppenheimer lifted their price target on shares of Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Biogen presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.70.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.